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Abstract
Objectives A major challenge faced with the manufacture of liposomes is the
high volumes of organic solvents used during manufacturing. Therefore, we have
implemented an organic solvent-free production method for drug-loaded lipo-
somes and demonstrated its applicability with both aqueous core-loaded and
bilayer-loaded drugs.
Methods Liposomes were produced by high shear mixing dry powder lipids with
an aqueous buffer, followed by down-sizing using a Microfluidizer processor.
Liposomes were purified via tangential flow filtration and characterised in terms
of size, polydispersity index, zeta potential and drug loading.
Key findings Doxorubicin-loaded PEGylated liposomes can bemanufactured using
this solvent-free method with particle sizes of 100–110 nm, low polydispersity index
(PDI) (<0.2) and high drug loading (97–98%). If required, liposomes can be further
down-sized via microfluidic processing without impacting drug loading. Similar
results were achieved with non-PEGylated liposomes. With bilayer-loaded ampho-
tericin B liposomes, again liposomes can be prepared within a clinically appropriate
size range (100–110 nm in size, low PDI) with high drug loading (98–100%).
Conclusions We apply a simple and scalable solvent-free method for the pro-
duction of both aqueous core or bilayer drug-loaded liposomes.
Introduction
Liposomes have been extensively investigated for the deliv-
ery of both hydrophobic and hydrophilic drugs due to their
ability to improve drug efficacy through targeting.[1] The
number of liposomal approvals (Table 1) continues to
grow in the United States (US)[2] and European Union
(EU).[3] Furthermore, with many of the patents related to
liposomal products expiring, there has been a rapid
increase in the number of generic liposome products
approved.[4] Table 2 summarises the rise in generic ver-
sions of the most successful and well-established products
such as Caelyx/Doxil (PEGylated liposomal doxorubicin)
and AmBisome (liposomal amphotericin B).
In the production of liposomes, both at the bench-scale
and within large-scale production, organic solvents are
commonly used, with examples outlined in Table 3. At the
bench-scale, the thin film hydration method remains the
most widely adopted method to manufacture liposomes
and it is based on the dissolution of the lipid components
with or without a drug in an organic solvent. The solvent is
subsequently evaporated by rotary evaporation, followed by
hydration of the film using an aqueous buffer. Other meth-
ods to produce liposomes include reverse-phase evapora-
tion and ethanol injection.[5] When considering the choice
of solvent, safe handling, removal and disposal is a key con-
sideration as organic solvents can be associated with
chronic health effects, especially halogenated solvents[6]
and maximum allowable concentration limits for solvents
within formulations are defined by the International Coun-
cil for Harmonisation of Technical Requirements for Phar-
maceuticals for Human Use (ICH) guidelines.[7] Solvents
are grouped into four classes as per the ICH Q3C guide-
lines. Class 1 solvents are known as human carcinogens and
suspected to be hazardous to the environment. Class 2 sol-
vents (chloroform and methanol) should be limited as they
are possible causative agents of irreversible toxicity. The
acceptable concentration limit for chloroform and metha-
nol is 60 and 3000 ppm, and the exposure limit is 0.6 and
30 mg/day, respectively. Ethanol is class 3 with a
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concentration limit of 5000 ppm.[7] Considering these
issues, various approaches have reported using less haz-
ardous solvents such as isopropyl alcohol[8] and ethanol.[9]
Given these issues and the need to develop more sus-
tainable production practices, we have investigated and
developed an easy-to-adopt manufacturing method for drug-
loaded liposomes that does not require the use of organic sol-
vents (Figure 1). Liposome size control was achieved using
the electric benchtop laboratory M110P Microfluidizer pro-
cessor. Using this solvent-free and scalable process, we have
manufactured doxorubicin-loaded liposomes (PEGylated
and non-PEGylated) and amphotericin B-loaded liposomes
with physicochemical attributes mapped to clinically
approved products in terms of size and drug loading.
Materials and Methods
Materials
Egg phosphatidylcholine (Egg PC), hydrogenated soy phos-
phatidylcholine (HSPC), 1,2-distearoyl phosphatidylcholine
(DSPC), 1,2-distearoyl-sn-glycero-3-phospho-(10-rac-glycerol)
(DSPG) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
Table 1 Marketed liposomal products, first approval and expected patent expiry dates[30,31]
Brand name Drug Indication
First
approval
Patent
expiry
Abelcet Amphotericin B Fungal infections 1995 2014
AmBisome Amphotericin B Fungal infections 1990 (EU)/
1997(US)
2008/2016
Amphotec Amphotericin B Fungal infections 1996 2015
Arikayce Amikacin Mycobacterium avium complex lung disease 2018 2037
Caelyx (EU)/
Doxil (US)
Doxorubicin hydrochloride
(PEGylated)
Breast neoplasms; multiple myeloma; ovarian neoplasms;
Kaposi’s sarcoma
1995 2014
DaunoXome Daunorubicin Cancer advanced HIV-associated Kaposi’s sarcoma 1996 2015
DepoCyt Cytarabine/Ara-C Neoplastic meningitis 1999 2018
DepoCyta Cytarabine Meningeal neoplasms 1999 2018
DepoDur Morphine Pain relief 2004 2017
Epaxal Inactivated hepatitis A virus (strain
RGSB)
Hepatitis A 1993 2012
Exparel Bupivacaine Anaesthetic 2011 2018
Inflexal Inactivated haemagglutinin of
Influenza virus strains A and B
Influenza 1997 2016
Marqibo Vincristine Philadelphia chromosome-negative acute lymphoblastic
leukaemia
2012 2020
Mepact Mifamurtide Osteosarcoma 2009 2028
Myocet Doxorubicin hydrochloride Breast neoplasms 2000 2019
Nocita Bupivacaine Long-acting local anaesthetic 2017 2036
Onivyde Irinotecan Combination therapy with fluorouracil and leucovorin in
metastatic adenocarcinoma of the pancreas
2015 2034
Visudyne Verteporfin Macular degeneration, degenerative myopia 2000 2016
Vyxeos Daunorubicin/cytarabine Acute myeloid leukaemia 2017(US)
2018 (EU)
2036 (US)
2037 (EU)
aProduction stopped due to manufacturing issues.
Table 2 Generic doxorubicin and amphotericin B liposomal products
and their manufacturer
Drug
Original
product
Generic
version Manufacturer
Doxorubicin
Hydrochloride
Doxil Adropeg 20 Axiommax Oncology
Pvt. Ltd
DOXOrubicin Dr. Reddy’s
Doxulip United Biotech
i-dox Getwell
Lipodox Sun Pharma
Lippod Celon Labs
Natdox-LP Natco Pharma Ltd.
Pegadria 50 Intas
Pharmaceuticals
Ltd.
Rubilong Zuventus Healthcare
Ltd.
SinaDoxosome Exir Nano Sina Co
Amphotericin B AmBisome Abhope Abbott
Ambilip United Biotech
Amflight Celon Labs
Amphonex Bharat serums and
vaccines Ltd.
Phosome 10 Cipla
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N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG 2000) were
obtained from Lipoid (Ludwigshafen, Germany). Sodium succi-
nate, cholesterol (SyntheChol), amphotericin B, 2-hydrox-
ypropyl-cyclodextrin, citric acid, sodium citrate tribasic,
L-histidine, ammonium sulfate, doxorubicin HCl European
Pharmacopoeia reference standard, sodium azide (NaN3) and
ammonium bicarbonate (NH4HCO3) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Sucrose and sodium
hydroxide were obtained from Fisher Scientific, Loughborough,
UK.Dialysis tubing 300 kD andmPES 750 and 100 kD columns
were purchased from Repligen Corporation, California, USA.
Other chemicals were used at analytical grade, and mQ-water
was provided by an in-house system.
Methods
Organic solvent-free manufacturing of
doxorubicin-loaded liposomes
Empty PEGylated and non-PEGylated liposomes
(HSPC : Chol : DSPE-PEG2000 56 : 38 : 5 and Egg
PC : Chol 45 : 55 molar ratio) were prepared by mixing
powdered lipids and cholesterol with 100 mL of hydration
buffer at 70 °C as per Table 4. The lipid dispersion was
high shear mixed (high shear mixer IKA T25 basic with S
25 N – 18 G dispersing tool) at 8000 rpm for 1 h at 70 °C.
Liposomes were size reduced at 65–70 °C using the M110P
Microfluidizer processor (Microfluidics Inc., Westwood,
MA, USA). Water was circulated at a temperature above
the transition temperature of the phospholipids (70 °C) in
the heat exchanger to achieve the necessary fluidity of the
liposomal bilayer for particle size reduction. The M110P
Microfluidizer processor was primed with buffer, and sam-
ples were processed at pressures of 5000 psi, 8000 psi,
15 000 psi, 18 000 psi and 20 000 psi for up to three pro-
cessing passes. Formulations were subjected to tangential
flow filtration (TFF) for buffer exchange and concentration
control (Figure 1). Doxorubicin was subsequently added to
liposomes and incubated at 60 °C for 10 min to actively
load the drug using a pH gradient.
Organic solvent-free manufacturing of ampho-
tericin B-loaded liposomes
Succinate buffer (10 mM, pH 2) with sucrose (9% w/v) was
heated at 70 °C using a water bath. DSPG (63.3 mg) was
added to succinate buffer and high shear mixed for 15 min.
Basic amphotericin B solution (37.6 mg) was prepared
using 2 M sodium hydroxide. Amphotericin B solution was
added to the acidified DSPG suspension at 70 °C and vor-
texed for 15 min. The DSPG-amphotericin B suspension
(pH 5.5) was high shear mixed for 1 h at 70 °C with pow-
dered HSPC (159.8 mg) and cholesterol (39.3 mg). Lipo-
somes (batch size 100–500 mL) were size reduced at 65–
70 °C using the M110P Microfluidizer processor at 25 000
psi for three passes.
Characterisation of particle size, polydispersity
and zeta potential using dynamic light scattering
The particle size, measured as the hydrodynamic diameter,
polydispersity index (PDI) and zeta potential were mea-
sured by dynamic light scattering using a Zetasizer Nano
ZS (Malvern Panalytical Ltd, Worcestershire, UK)
Table 3 Methods and solvent used during manufacturing of
liposomes
Method Mechanism Solvents
Bangham
method[32-34]
Rehydration of thin lipid
film
Chloroform and
methanol
Reverse-phase
evaporation[35]
Aqueous phase added
to the organic phase
and evaporated to
form liposomes
Diethyl ether, isopropyl
ether, halothane and
trifluorotrichloroethane
Detergent
depletion[36]
Liposomes formed
through detergent lipid
interaction
Chloroform and
methanol
Microfluidic
channel[37,38]
In-line precipitation of
liposome from the
organic phase into
aqueous
Ethanol, methanol and
isopropyl alcohol
Dense Gas
method[35]
Use of dense gas as a
solvent for lipids
instead of organic
solvents
Ethanol and methanol
Ethanol/ether
injection[39-41]
Precipitation of liposome
from the organic phase
into aqueous
Ethanoland diethyl ether
Supercritical
fluid
method[35]
Use of supercritical
fluids as a solvent for
lipids instead of
organic solvents
Ethanol and methanol
Supercritical
antisolvent
method[42]
Lipids dissolve readily in
scCO2 and then
precipitate in the form
of ultrafine particles
Chloroform,methanol
and ethanol
Dual
asymmetric
centrifugation
method[35,43]
Highly concentrated
lipid dispersion system
diluted by a suitable
aqueous phase during
centrifugation
Chloroform, methanol
and ethanol
Membrane
contactor
method[44]
The aqueous phase is
poured into the
module by the action
of a pump, while the
organic phase is placed
in the pressurised
vessel
Ethanol
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equipped with a 633 nm laser and a detection angle of
173°. Samples were diluted to 0.2 mg/mL lipid concentra-
tion in water, and the values of water were used for refrac-
tive index and viscosity. Zetasizer Software v.7.11 (Malvern
Panalytical Ltd.) was used for the acquisition of data.
Removal of free drug and buffer exchange with
tangential flow filtration
Liposomes were purified by TFF using a KrosFlo KR2i
system (Waltham, MA, USA) and mPES 750 kD and
100 kD columns for amphotericin B and doxorubicin
formulations, respectively. Formulations were concen-
trated to achieve final lipid concentrations (28, 16 and
8 mg/mL for amphotericin B, PEGylated and non-PEGy-
lated doxorubicin-loaded liposomes, respectively) and
washed for 10 diafiltration cycles per 1 mL of formula-
tion using an appropriate buffer for buffer exchange and
to remove unentrapped drug.
Quantification of drug loading
Quantification of doxorubicin was performed using a
microplate reader model 680 (Bio-Rad Laboratories. Inc.,
Hertfordshire, UK) measuring the UV absorbance at
490 nm. Liposomes were solubilised with 50% 2-propra-
nolol (v/v). Calibration curves were performed under the
same conditions as the samples. The limit of detection
(LOD) and quantification (LOQ) were 0.05 and 0.15 mg/
mL, respectively. Quantification of amphotericin B was
performed by reverse-phase high-performance liquid chro-
matography (HPLC) (Agilent 1100) using a UV-VIS detec-
tor connected to the instrument. A Gemini C18 column
with 110 A pore size 150 9 4.60 mm 5 lm (Phenomenex,
Macclesfield, UK) was used as a stationary phase. A 1 mL/
min flow rate was used with an 18 min elution gradient,
composed of solvent A (0.1 % perchloric acid in water) and
solvent B (100% acetonitrile) at 408 nm. Initially, the gradi-
ent increased from 95 : 5 (A : B) to 5 : 95 (A : B) at 5 min,
before returning to an initial composition of 95 : 5 (A : B)
at 15 min which was maintained for 2 min until the end of
the analysis. The sample injection volume was 20 µL. LOD
and LOQwere 0.09 and 0.28 µg/mL, respectively.
Morphological characterisation of liposomes via
CryoTEM
Samples for microscopy were prepared by placing 5 µL of
liposomes onto a 400-mesh lacey carbon-coated grid using
single-sided blotting for 2 s, then immediately immersing
the sample grid into nitrogen-cooled ethane (100%
ethane). Liposome morphology was then observed using
the Jeol Jem F-200 microscope (Joel, Tokyo, Japan) at liq-
uid nitrogen temperature and 200 kV.
Drug release studies using USP-4 dissolution
apparatus
The effect of manufacturing conditions, including pressure
and number of passes, on doxorubicin release was studied
Figure 1 Schematic representation of liposome manufacture, buffer exchange/purification, drug loading and sterilisation. Liposomes were manu-
factured by adding powdered lipids to aqueous buffers without organic solvents (1), processed using high-pressure homogenisation (M110P
Microfluidizer processor) (2), and subjected to tangential flow filtration for buffer exchange and purification (3), and finally, drug-loaded liposomes
were sterile-filtered using a 0.22µm filter (4).
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using USP-4 flow-through CE7-smart (SOTAX) apparatus
using a method previously developed by Yuan et al.[10]
which was shown to offer discriminatory assessment of
liposomal drug release from these formulations. Briefly,
0.8 mL of 2 mg/mL free doxorubicin (in 10% w/v sucrose
and 10 mM histidine, pH 6.5) or doxorubicin-loaded lipo-
somes was placed in 300 kD dialysis tubes and inserted into
USP-4 flow-through cells with 39.2 mL 100 mM
NH4HCO3, 75 mM 2-(N-morpholino) ethane sulfonic acid
(MES), 5% w/v hydroxypropyl-cyclodextrin (HP-CD), 5%
w/v sucrose and 0.02% w/v NaN3 (pH 6) as a release med-
ium (the total volume of release media was 40 mL, and the
final doxorubicin concentration in the release media was
equivalent to 20 lg/mL). The flow rate and running tem-
perature of the release medium were set at 16 mL/min and
45 °C, respectively.[10] The cumulative release was calcu-
lated as the percentage of the calculated doxorubicin con-
centration from the liposomes at each time point, divided
by the detected concentration of free doxorubicin from the
control at the same time point. A UV plate reader at
490 nm was used for this purpose (300 µL/well).[10]
Results
Size-controlled high drug-loaded liposomes
can be produced by the solvent-free method
To investigate the effect of pressure and number of
homogenisation passes during manufacturing, PEGylated
liposomes (as per Table 4) were prepared using the organic
solvent-free technique at an 8 mg/mL lipid concentration.
After initial hydration of the lipids and production of mul-
tilamellar vesicles, liposomes had a z-average diameter of
approximately 1500 nm and a D90 of approximately
2600 nm (Figure 2). Liposomes were then down-sized at
15 000, 18 000 and 20 000 psi with up to three homogeni-
sation passes using the M110P Microfluidizer processor.
Figure 2 shows that the pressure and number of passes
adopted during manufacturing significantly control lipo-
some size and PDI. Formulations manufactured at 15 000
psi significantly reduced (P < 0.05) the z-average diameter
to approx. 100 nm at pass 3 with a PDI of 0.29. The D50
size was similar to the z-average, with the D90 being
approximately 200 nm (Figure 2). To enhance size reduc-
tion, higher pressures were adopted (Figure 2); at 18 000
psi, liposomes significantly decreased in size (P < 0.05) to
120 nm after 1 pass, down to 95 nm (z-average diameter)
by pass 3 (0.19 PDI). The D10, D50 and D90 also reduced
in a similar pattern (Figure 2). Further increasing the pres-
sure to 20 000 psi produced the most rapid size reduction
(P < 0.05) and the smallest particles with only two passes
being required to achieve <100 nm size and PDI < 0.2
(Figure 2). Across all formulations, the zeta potential was
in the range of 5 to 5 mV, with no significant impact
from the amount of pressure used. In general, the pressure
was the parameter affecting the physicochemical character-
istics the most, with all three pressures giving values signifi-
cantly different from each other (P < 0.05). After the first
pass, the number of passes did not significantly affect the
vesicle size. However, the main vesicle characteristic
affected here was the PDI (P < 0.05). After the second pass,
the PDI reached a plateau of around 0.2 for pressures
18 000 and 20 000 psi (Figure 2).
To further explore this, PEGylated liposome formula-
tions were manufactured at 18 000 and 20 000 psi, and a
pH gradient established by exchanging the external buffer
from 250 mM ammonium sulfate (pH 5.5) to sucrose-his-
tidine using TFF. Doxorubicin was then loaded into these
formulations, and finally, the formulations were sterilised
(0.22 µm filtration) (Figure 3). Particle size (z-average
diameter) after production at 18 000 psi was approx.
105 nm after two passes, dropping to 95 nm after three
passes. At 20 000 psi, the sizes dropped by approximately
10 nm to 95 and 85 nm after passes 2 and 3, respectively
(Figure 3). Across all four test parameters, the PDI of the
liposomes remained low (<0.2) demonstrating a high level
of homogeneity. With these formulations, which were still
in ammonium sulfate buffer and without drug-loaded, the
zeta potential is neutral (Figure 3). Liposomes were then
subjected to buffer exchange (using histidine-sucrose buf-
fer) to set up the pH gradient. This did not significantly
change the particle size of the various liposomes but did
significantly (P < 0.05) reduce the zeta potential to 35 -
40 mV for all four preparations tested (Figure 3). Using
the established pH gradient, liposomes were actively loaded
with doxorubicin. Drug loading was >90%, irrespective of
the pressure or number of passes used for the formulations
(Figure 3), while subsequent sterilisation had no significant
effect on these attributes.
Liposomes prepared by the organic solvent-free method
were compared to liposomes produced via the traditional
Table 4 Doxorubicin-loaded formulation composition used during
manufacturing
Composition PEGylated formulation
Non-PEGylated
formulation
HSPC 4.8 mg/mL –
EggPC – 3.9 mg/mL
DSPE-PEG
2000
1.6 mg/mL –
Cholesterol 1.6 mg/mL 1.6 mg/mL
Doxorubicin 2 mg/mL 2 mg/mL
Hydration
buffer
250 mM Ammonium sulfate
pH 5.5
300 mM Citrate
buffer pH 5.5
External
buffer
Sucrose-Histidine pH 6.5 Sodium carbonate pH
7.3
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lipid hydration and sonication method (Figure 4). These
liposomes were prepared using either HSPC or DSPC as
the base lipid. With the lipid hydration method, the z-aver-
age diameter was around 100–120 nm, with low PDI (<0.2)
and high drug loading (>90%). CryoTEM images show
classical oval-/ellipsoidal-shaped liposomes as a result of
the formation of long nanocrystals of doxorubicin-sulfate
within the aqueous phase. When these formulations were
prepared by the solvent-free method, comparable liposome
morphology can be seen irrespective of the base lipid used
(Figure 4).
Pressure and number of passes influence
liposome particle size but not doxorubicin
release
To further investigate the impact of manufacturing attri-
butes, doxorubicin-loaded PEGylated liposomes were pre-
pared and subjected to drug release testing using the USP-4
dissolution apparatus with a protocol previously developed
to discriminate between doxorubicin-loaded liposomes.[10]
From the results in Figure 5a, we can see that there were no
significant differences in doxorubicin release profiles of
liposomes prepared after two or three passes at 18 000 or
20 000 psi, with approximately 60% doxorubicin release
after 6 h. On the other hand, free doxorubicin showed
100% release after 2 h (Figure 5a). Additionally, we can see
that the PDI was unchanged after drug release, with 0.2
PDI irrespective of the down-sizing pressure (Figure 5b).
However, particle sizes significantly (P < 0.05) decreased
after drug release, possibly as a result of the loss of the drug
nanocrystals within the liposomes.
Solvent-free production can also be applied
to non-PEGylated liposomes
To further investigate whether doxorubicin-loaded non-
PEGylated liposomes (Egg PC : Cholesterol) can be manu-
factured using the solvent-free manufacturing technique,
empty formulations (as per Table 4) were prepared at
5000, 8000, 10 000, 15 000 and 18 000 psi. Once again, the
z-average diameter, PDI and zeta potential were measured
at each pass. By increasing the pressure during manufactur-
ing, liposome size significantly (P < 0.05) decreased from
287 to 137 nm (pass 1 to 3; 5000 psi), from 217 to 117 nm
(8000 psi), from 126 to 103 nm (10 000 psi), from 110 to
89 nm (15 000 psi) and from 103 to 78 nm (18 000 psi)
(Figure 6a). Regarding PDI, formulations manufactured
above 10 000 psi pressure produced homogeneous suspen-
sions with PDI commonly below 0.2 at pass 3 (Figure 6a).
Across all the formulations, the zeta potential remained
neutral, with values between 5 and 5 mV (Figure 6b).
Based on these results, non-PEGylated liposomes were
characterised after production at 18 000 psi, subjected to
buffer exchange using TFF and loaded with doxorubicin.
The formulations were sterilised via 0.22 µm filtration
Figure 2 Effect of pressure and number of passes on PEGylated formulation. Particle size (z-average diameter, nm), D-value intercepts for 10%, 50% and
90%of the cumulativemass (D10, D50, D90; based on intensity), PDI and zeta potential (mV)weremeasured during processing using theM110PMicrofluidizer
processor. Empty HSPC : Chol : DSPE-PEG2000 liposomes were manufactured as outlined in Table 4 at8 mg/mL lipid concentration using 15 000, 18 000
and 20 000 psi for three passes. Results representmean  SD from three independent batches.
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(Figure 7). After three microfluidic passes, purification and
sterilisation, liposomes were 90–100 nm in size, unimodal
in nature (PDI values < 0.2) and with high drug loading
(>75%) (Figure 7a–c). With this formulation, liposomes
encapsulate doxorubicin-citrate rather than doxorubicin-
sulfate similar to the marketed formulation Myocet. This
results in a different structural morphology (Figure 7d)
with CryoTEM images of doxorubicin fibre bundles having
straight, curved and circular geometries due to the fibres
being more flexible than doxorubicin-sulfate. These results
show that by using the organic solvent-free method, we can
manufacture doxorubicin-citrate-loaded, non-PEGylated
liposomes with physicochemical attributes comparable to
Myocet (Figure 7).
Solvent-free production can also be adopted
to manufacture amphotericin B-loaded
liposomes
The applicability of the organic solvent-free technique to
manufacture liposomes with a water-insoluble drug was
also demonstrated by preparing amphotericin B-loaded
liposomes. For this formulation, a pressure of 25 000 psi
was employed (based on pilot data; data not shown) with
up to three passes of homogenisation applied using M110P
Microfluidizer processor (Figure 8a). During size reduc-
tion, the anionic zeta potential of the liposomes remained
between 40 and 50 mV (Figure 8b) and the liposomes
became unimodal in nature (Figure 8c). Again, manufac-
turing this formulation with M110P Microfluidizer proces-
sor showed high (98–100%) drug loading throughout the
homogenisation process (Figure 8d). Using this manufac-
turing process, we were able to produce amphotericin B-
loaded liposomes of 100–110 nm particle size, with a 0.2
PDI (Figure 8e) which are generally single or bilamellar in
nature (Figure 8f).
Liposome composition influences size
reduction capability
To further consider the impact of lipid choice and lipid
concentration, formulations containing low transition
lipids (Egg PC) and high transition lipids (HSPC), with or
without DSPE-PEG2000 and DSPG, were prepared at
higher concentrations to determine the highest manufac-
turing concentration limits using the organic solvent-free
Figure 3 Effect of pressure and number of passes on the PEGylated formulation: Particle size, PDI and drug loading. Liposomes were manufac-
tured as outlined in Table 4 at 18 000 and 20 000 psi for two or three passes. Formulations were subjected to tangential flow filtration for buffer
exchange, followed by the addition of doxorubicin to load into the liposomes. Doxorubicin-loaded liposomes were sterile-filtered using 0.22µm fil-
ters. Results are shown as (a) particle size (z-average diameter, nm) and PDI (columns and open circles, respectively), (b) zeta potential (mV) and
(c) % drug loading of doxorubicin. Results represent mean  SD from three independent batches.
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Figure 4 The physicochemical characteristics and morphology of PEGylated doxorubicin-loaded liposomes. HSPC and DSPC liposomes with dox-
orubicin loaded via a pH gradient (intravesicular salt solution: 250 mM ammonium sulfate, pH 5.5; extraliposomal buffer: sucrose-histidine pH 6.5)
were prepared by either conventional lipid thin film hydration followed by sonication (solvent-based, laboratory scale) or with the organic solvent-
free method (solvent-free, scalable manufacture).
Figure 5 Doxorubicin release profiles of PEGylated doxorubicin-loaded liposomes using flow-through USP-4 apparatus. Final doxorubicin concen-
tration in the release media was equivalent to 20 lg/mL, and doxorubicin release profile was investigated over 6 h at 45 °C. Results are shown as
(a) effect of pressure and number of passes during manufacturing on doxorubicin release and (b) particle size (z-average diameter, nm) and PDI
(columns and open circles, respectively) before and after doxorubicin release. Results represent mean  SD from three independent batches.
© 2020 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd
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method (Figure 9). Our results suggest that Egg PC-based
liposomes can be easily prepared at concentrations up to
60 mg/mL total lipid with PDI values of <0.2 being
achieved at 3–5 processing passes (Figure 9a–c). With
HPSC-based formulations (Figure 9d–f), the addition of
DSPG or DSPE-PEG2000 tended to allow higher concen-
trations of lipids to be used compared with HSPC : Chol
formulations (40 mg/mL for HSPC : Chol (Figure 9d)
compared with 80 mg/mL for formulations containing
DSPE-PEG2000 or DSPG; Figure 9e,f).
Discussion
There are a range of conventional methods available to
manufacture liposomal formulations, for example, the lipid
hydration method, detergent depletion, ether/ethanol injec-
tion, reverse-phase evaporation and emulsion meth-
ods.[5,11] It should be noted that the majority of
conventional liposome preparation procedures involve the
use of organic solvents (Table 3). When we consider larger
scale production of liposomes, and nanomedicines in gen-
eral, the use of solvents and issues with scalable production
methods present challenges. Indeed, manufacturing issues
can lead to supply shortage and eventually stoppage asseen
with the Doxil/Caelyx product.[12]
Here, we demonstrate an organic solvent-free method to
produce a selection of drug-loaded liposomes based on
clinically approved products including those incorporated
within the aqueous core (Doxil and Myocet) and those
where the drug is incorporated within the bilayer (AmBi-
some). In all three formulations, the drug is loaded within
the liposomes to improve targeting of the drug and reduce
off-target toxicity. For Doxil (PEGylated liposomes) and
Myocet (non-PEGylated liposomes), the drug is loaded
after liposome production via remote loading[13] and for-
mulations mapped to both of these marketed formulations
can be produced without solvent (Figures 4 and 7, respec-
tively). When doxorubicin is remotely loaded into PEGy-
lated liposomes via a transmembrane ammonium sulfate
gradient, long nanocrystals of doxorubicin-sulfate are
formed in the aqueous phase generating ellipsoidal lipo-
somes[14] as confirmed in Figure 4. With AmBisome, the
drug is incorporated within the bilayer during production.
Amphotericin B is very poorly soluble in aqueous media[15]
and highly soluble in hydrophobic media such as lipid
membrane bilayers.[16] An increase in solubility and reduc-
tion of toxicity can be achieved by conversion of oligomers
of amphotericin B to hetero-aggregates containing deter-
gents or lipids,[15] including liposomal bilayers.[17] Liposo-
mal amphotericin B formulations are thus less toxic than
conventional formulations and more effective in treating
fungal infections allowing for higher exposure and longer
duration of therapy.[18–20] Currently, manufacturing steps
of AmBisome involve solubilisation of lipids in an organic
Figure 6 Effect of pressure and number of passes on particle size, PDI and drug loading of the non-PEGylated liposome formulation. Empty
non-PEGylated liposomes were manufactured as outlined in Table 4 at 5000, 8000, 10 000, 15 000 and 18 000 psi for three passes. Results are
shown as (a) particle size (z-average diameter, nm) and PDI (columns and open circles, respectively) and (b) zeta potential (mV). Results represent
mean  SD from three independent batches.
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solvent such as chloroform and methanol, acidification of
lipids and drug complex, removal of solvent and hydration
to form liposomes followed by size reduction.[21,22] Fig-
ure 8 demonstrates that amphotericin B-loaded liposomes
can be manufactured by an organic solvent-free technique
using the M110P Microfluidizer processor. In this manu-
facturing process, the amphotericin B and DSPG complex
remains an essential element.[23] Since amphotericin B is
water-insoluble, it is difficult to make a complex in an
aqueous phase. Therefore, the solubility of amphotericin B
was altered using the protonation of the amine group from
amphotericin B. Acidified DSPG receives the proton from
amphotericin B and forms a complex in aqueous phases.
Using the developed organic solvent-free method, we are
able to produce liposome products that map to the physic-
ochemical specifications of each of these marketed products
at high throughputs. When using the high-pressure
Microfluidizer technology, we are able to produce lipo-
somes from bench-scale to high throughput. Size reduction
of the liposomes is achieved by the layers of liposomes
being stripped away during homogenisation. This results in
liposomal formulations with a narrow size distribution.
With this process, selection of pressure and number of
passes during manufacturing are both critical process
parameters as both impact on particle size and PDI. How-
ever, within our studies, we see no evidence of impact on
zeta potential, drug loading and drug release. Therefore, we
demonstrate that liposomal formulations can be manufac-
tured and particle size controlled through a range of pres-
sures and number of homogenisation passes.
Studying the release profile of generic liposome formula-
tions, such as the doxorubicin formulations, is important
for quality control and comparability studies.[10] To exam-
ine drug release from the liposomal formulations, we used
Figure 7 In-process manufacturing characterisation of the doxorubicin-loaded non-PEGylated formulation. Liposomes were manufactured as out-
lined in Table 4 at 20 000 psi for three passes. Formulations were subjected to tangential flow filtration for buffer exchange followed by the addi-
tion of doxorubicin to load into the liposomes. Doxorubicin-loaded liposomes were sterile-filtered using a 0.22µm filter. Results are shown as (a)
particle size (z-average diameter, nm) and PDI (columns and open circles, respectively), (b) % drug loading of doxorubicin and (c) particle size
intensity plots. CryoTEM images of the liposomes are shown in (d). Results represent mean  SD from three independent batches
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Figure 8 Formulation characterisation of the amphotericin B-loaded formulation. Liposomes were manufactured at 25 000 psi for three number
of passes. Formulations were subjected to tangential flow filtration to remove unentrapped amphotericin B and were sterile-filtered using a
0.22µm filter. Results are shown as (a) particle size (nm) and PDI (columns and open circles, respectively), (b) zeta potential (mV), (c) particle size
intensity plots, (d) % drug loading of amphotericin B and (e) post-sterilisation formulation characteristics. CryoTEM images of the liposomes are
shown in (f). Results represent mean  SD from three independent batches
Figure 9 The impact of lipid choice on manufacturing concentration limits (1–8% w/v lipids to buffer). Liposomes were prepared at 20 000 psi
at high concentrations and particle size (nm) and PDI (columns and open circles, respectively) measured. (a) Egg PC : Cholesterol (3 : 1 w/w
(60 mg/mL), (b) Egg PC : Cholesterol : DSPE-PEG 2000 (3 : 1 : 1 w/w; 60 mg/mL), (c) Egg PC : Cholesterol : DSPG (3 : 1 : 1 w/w; 80 mg/mL), (d)
HSPC : Cholesterol (3 : 1 w/w; 40 mg/mL), (e) HSPC : Cholesterol : DSPE-PEG 2000 (3 : 1 : 1 w/w; 80 mg/mL) and (f) HSPC : Cholesterol : DSPG
(3 : 1 : 1 w/w; 80 mg/mL)
© 2020 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd
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a dialysis insert set-up of USP-4. From Figure 5, we can see
that over 50% of doxorubicin released from liposomes in
6 h (as previously shown ref.[10]). Furthermore, the dox-
orubicin release pattern was not affected by liposome pro-
duction at different pressures nor the number of passes,
indicating the performance of liposomes was not affected
due to the selected manufacturing parameters which can be
adopted as normal operational parameter settings.
When considering the impact of lipid choice on manu-
facturing concentration limits, not only bilayer rigidity and
transition temperature,[24] but also hydrophilic chains and
charge of lipids play an important factor. Results from Fig-
ure 9 demonstrated that in the presence of PEG chains or
anionic lipids, at higher lipid concentrations, smaller parti-
cle sizes were observed. This may be due to the tendency
for PEG to be packed at highly curved surfaces towards the
aqueous phase because of its large head group which pro-
motes the formation of smaller liposomes.[25] Also, PEG
provides a strong inter-bilayer repulsion on the surface of
liposomes.[26,27] These act to stabilise liposome prepara-
tions by overcoming the attractive Van der Waals forces
and thus avoid aggregation. Since the attachment of PEG
molecules to the surface of liposomes or anionic charge
from DSPG strongly reduces the attractive forces (Van der
Waals), and increases the repulsive forces (steric, electro-
static and hydration),[28,29] addition of PEG or DSPG
causes disaggregation of liposome assemblies and a reduc-
tion of liposome size.
Conclusions
From our studies, we demonstrate organic solvent-free
manufacturing of various liposome formulations including
liposomes loaded with either doxorubicin or amphotericin
B. Using the M110P Microfluidizer processor, we were able
to replicate liposome physicochemical attributes of prod-
ucts currently approved for clinical use. Using this process,
down-sizing of liposomes can be run at a flow rate of up to
120 mL/min with guaranteed scalability. Critical process
parameters that controlled particle size and polydispersity
were the operating pressure and number of passes.
However, these did not impact drug loading (either within
the aqueous core or the lipid bilayer), nor drug release
when tested. This allows us to manipulate the running pres-
sure and pass number to produce liposomes within a given
target size range. Lipid concentrations of up to 80 mg/mL
were processed using this manufacturing method, with
liposome composition being a factor to consider when
identifying optimal concentration ranges.
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